These cell lines, which included a range of cancer types (lung, melanoma, or breast) and oncogenic drivers (KRASG12S, BRAFV600E, and PTEN, respectively) [22], showed accumulation of NRAS and KRAS under MEKi treatments (Figure 1A–C). This evidence concerns the gene NRAS and melanoma.